NICE Backs Belantamab Mafodotin for Relapsed Myeloma

NICE has recommended belantamab mafodotin for relapsed multiple myeloma, with trial data showing remissions of more than 3 years.
Medscape News UK

Source link : https://www.medscape.com/viewarticle/nice-backs-belantamab-mafodotin-relapsed-myeloma-2026a1000bx0?src=rss

Author :

Publish date : 2026-04-16 15:38:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

NICE Backs Belantamab Mafodotin for Relapsed Myeloma

One in 10 Pharmacies Cloned by Fake Jab Sellers

AI Chat Offered Small Mental Health Boost to College Students in Distress

Related Posts

Why Is Sexual Health Still Overlooked in Chronic Pain Care?

FDA Approves Hyaluronic Acid Filler for Reducing Neck Lines

‘Game-changing’ cancer service approved for rollout

Ancient monument may have been an early Stonehenge prototype

No young women have died of cervical cancer in England for years

Cervical cancer deaths fall to zero in young women given vaccine

Why Is Sexual Health Still Overlooked in Chronic Pain Care?

FDA Approves Hyaluronic Acid Filler for Reducing Neck Lines

‘Game-changing’ cancer service approved for rollout

Ancient monument may have been an early Stonehenge prototype

No young women have died of cervical cancer in England for years

Cervical cancer deaths fall to zero in young women given vaccine

Cefazolin Proves Its Mettle for Methicillin-Susceptible Staph Infections

FTC Sues Leading Transgender Health Group

Categories

Archives